Culture
We are F2G
We believe that the world’s greatest health challenges can be solved when radical hope is grounded in cutting-edge science. At F2G (Functional Fungal Genomics), we focus on developing first-in-class medicines to treat rare, life-threatening fungal infections. Our team has been on a 20-year journey, determined to unlock the potential of our science so that patients and caregivers can better fight their battle and go on to win their war.
The story of our novel agent began with a fortuitous discovery. Exploration of genes unearthed a promising class with extraordinary therapeutic potential. Over the next two decades, we followed our intuition and the science. We embraced challenges along the way. We found inspiration in our technology. And we committed ourselves to creating the chance for a better tomorrow.
Our team
Synergy happens when a world-class team of scientists and operational experts join forces to drive innovation. Our team has built biotechnology and pharmaceutical companies, launched successful first-in-class treatments, and harnessed deep knowledge in microbiology and biochemistry. Many years of unparalleled expertise are channeled into the therapies we create. Together, we aim to improve the treatment landscape in rare fungal infections.
The team is collaborative, supportive, and professional with no hidden agenda. Finally, it is fantastic to be able to work on a program that has therapeutic potential.”
Lesley Fitton
Executive Director, Clinical Operations
Management
Board of Directors
How we got here
Over the last two decades, our patient-first convictions have pushed us to embrace challenges and navigate courageously through the unknown. As we continue to advance solutions for rare infectious diseases, our story is a daily reminder of what’s possible when tenacious people follow the science toward novel, effective solutions.
Investors and partners
F2G is supported by a blue-chip investor syndicate, which includes:
F2G was awarded Bionow’s 2022 Investment Deal of the Year in recognition of our collaboration with Shionogi Co., Ltd. to develop and commercialise a novel antifungal agent for patients. This award is a testament to our global commitment to bringing a potentially life-saving therapy to patients with fungal infections.